Radiation Therapy Quality Assurance Analysis of Alliance A021501: Preoperative mFOLFIRINOX or mFOLFIRINOX plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the pancreas

CONCLUSION: Despite rigorous QA, we encountered variability in simulation, contouring, plan coverage, and dose on trial. While clinical outcomes did not appear to be impacted, findings from this analysis serve to inform subsequent PDAC SBRT trial designs and QA requirements.PMID:38492812 | DOI:10.1016/j.ijrobp.2024.03.013

Source: Health Physics - March 16, 2024 Category: Physics Authors: Leila T Tchelebi Diana Segovia Koren Smith Qian Shi T J Fitzgerald Michael D Chuong Tyler J Zemla Eileen M O'Reilly Jeffrey Meyerhardt Eugene J Koay Jessica Leif Ardaman Shergill Matthew Hg Katz Joseph M Herman Source Type: research